CAR‐T cells specific for CD19 have shown good efficacy and encouraging results in the treatment of relapsed and/or refractory (R/R) CD19 B cell acute lymphoblastic leukaemia (B‐ALL),1 but they also come with serious and potentially life‐threatening complications.2 This evidence concerns the gene CD19 and acute lymphoblastic leukemia.